Tradestie Institutional Equity Comparison Engine

VNDA vs CBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

VNDA Overall Edge

VNDA Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vanda Pharmaceuticals Inc. (VNDA) driven by superior Valuation, Growth & Margin while CBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, VNDA trades at 103.1x Forward P/E with -77.6% operating margin (+24.1% YoY revenue) versus CBIO at N/M Forward P/E and -1432.6% operating margin (+0.0% YoY). In options structure, VNDA sits in BREAKDOWN (75th %ile IV; Dealer Gamma Walls on Pro) against CBIO sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner VNDA
VNDA 103.1x vs CBIO N/M Fwd P/E
Growth & Margin Winner VNDA
Op Margin -77.6% vs -1432.6% ยท YoY +24.1% vs +0.0%
Momentum & Technical Winner CBIO
1Y -12.6% vs +1.7% ยท 52W Pos 4% vs 24%
Options & Structure Winner CBIO
BREAKDOWN (75th %ile IV) vs BREAKDOWN (10th %ile IV)
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
1M Return -5.83%
1Y Return -12.56%
Forward P/E 103.1x
Unified AI Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
CBIO NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.20
-6.71% 1D
Market Cap $533.8M
1M Return +11.49%
1Y Return +1.69%
Forward P/E N/M
Unified AI Score
37.4 / 100 SELL
Tech 35.0 Fund 46.0 Flow 63.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VNDA -12.56% CBIO +1.69% Spread: +14.25 pp (CBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period VNDA Revenue CBIO Revenue VNDA Op. Margin CBIO Op. Margin Margin Edge
FY2018 $190M N/A 11.3% N/A VNDA
FY2019 $230M N/A 10.0% N/A VNDA
FY2020 $250M $10M 11.0% -506.8% VNDA
FY2021 $270M $0M 15.7% -5470.7% VNDA
FY2022 $250M $0M 2.5% -63204.4% VNDA
FY2023 $190M $0M -7.2% -392752.9% VNDA
FY2024 $200M N/A -20.5% N/A VNDA
FY2025 $220M $10M -70.0% -1407.5% VNDA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VNDA (7) vs CBIO (3)
Institutional Metric VNDA CBIO Criterion Row Winner
Market Capitalization Scale $238.9M $533.8M Larger Scale CBIO
Trailing P/E Ratio Valuation 103.1x N/M Lower Multiple VNDA
Forward P/E Ratio Valuation 103.1x N/M Lower Multiple VNDA
Revenue Growth (YoY) Growth +24.1% +0.0% Higher Growth VNDA
Operating Margin (TTM) Profitability -77.6% -1432.6% Higher Margin VNDA
Net Profit Margin Profitability -119.9% 0.0% Higher Margin CBIO
Return on Equity (ROE) Capital Efficiency -82.5% -160.8% Higher ROE VNDA
52-Week Range Position Momentum 4% ($4โ€“$10) 24% ($9โ€“$27) Stronger Trend CBIO
Beta / 30D Volatility Risk Regime 1.25ฮฒ ยท 61% Vol 1.42ฮฒ ยท 63% Vol Lower Realized Risk VNDA
Unified Institutional Score Composite Signal 49.0 / 100 (HOLD) 37.4 / 100 (SELL) Higher Composite VNDA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VNDA vs CBIO Buy Guide
VNDA BREAKDOWN
174d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 75th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live VNDA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CBIO BREAKDOWN
144d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live CBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VNDA nor CBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.